Volume : 10, Issue : 11, November – 2023
Title:
PHARMACEUTICAL PROPERTIES OF MOMORDICA CHARANTIA LINNAEUS AND ITS POTENTIAL IN DIABETES MANAGEMENT
Authors :
Ahmad Alzahrani, Ahmed Almohammadi, Khalid Alkhormani, Abdullah Alotaibi, Adel Almalki, Abdulrahman Alotaibi, Hassan Alzahrani
Abstract :
Momordica Charantia Linnaeus, commonly known as bitter melon, has been traditionally used for its potential therapeutic properties, particularly in diabetes management. This paper aims to provide a comprehensive overview of the pharmaceutical properties, safety profile, and clinical efficacy of Momordica Charantia Linnaeus in diabetes management. The phytochemical composition of bitter melon, including charantin, polypeptide-p, and flavonoids, contributes to its antidiabetic, antioxidant, and anti-inflammatory effects (Ahmed et al., 2013; Grover & Yadav, 2004). Preclinical studies have demonstrated promising antidiabetic effects of bitter melon, such as blood glucose-lowering properties and preservation of pancreatic beta cell function (Ahmed et al., 2013; Grover & Yadav, 2004). However, clinical trials have yielded mixed results, highlighting the need for further research and standardization of study designs (Ooi et al., 2012). The safety profile of bitter melon is generally favorable, but some individuals may experience gastrointestinal disturbances and an increased risk of hypoglycemia (Grover & Yadav, 2004; Ooi et al., 2012). Additionally, bitter melon may interact with certain medications, necessitating caution and close monitoring in specific populations (Leung & Birtwhistle, 2009). In conclusion, Momordica Charantia Linnaeus shows potential as an adjunct therapy in diabetes management, but further research, including large-scale clinical trials, is needed to establish its efficacy, safety, and optimal usage guidelines (Grover & Yadav, 2004; Tiwari & Rao, 2002).
Key words:Momordica Charantia, Bitter melon, Diabetes management, Antidiabetic, Phytochemical composition, Charantin, Polypeptide-p, Flavonoids, Safety profile, Clinical efficacy, Preclinical studies, Clinical trials, Antioxidant, Anti-inflammatory, Medicinal plants
Cite This Article:
Please cite this article in Ahmad Alzahrani et al, Pharmaceutical Properties Of Momordica Charantia Linnaeus And Its Potential In Diabetes Management, Indo Am. J. P. Sci, 2023; 10 (11).
Number of Downloads : 10
References:
1. Ahmed, I., Adeghate, E., Cummings, E., & Sharma, A. K. (2013). Beneficial effects and mechanisms of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Molecular and Cellular Biochemistry, 372(1-2), 229-241.
2. Grover, J. K., & Yadav, S. P. (2004). Pharmacological actions and potential uses of Momordica charantia: a review. Journal of Ethnopharmacology, 93(1), 123-132.
3. Leung, L., & Birtwhistle, R. (2009). Kudingcha tea and diabetes mellitus: a review of pharmacology, toxicology and clinical studies. Journal of Pharmacy and Pharmaceutical Sciences, 12(3), 368-374.
4. Ooi, C. P., Yassin, Z., & Hamid, T. A. (2012). Momordica charantia for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 8(8), CD007845.
5. Tiwari, A. K., & Rao, J. M. (2002). Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. Current Science, 83(1), 30-38.